

Special Issue

Virus-Like Particle and Nano-Particle Vaccines 2.0

Message from the Guest Editors

Nanotechnology is entering an increasing number of branches of science and common life. Nanoparticles of various types have been investigated for a wide variety of applications, including biomedicine. The special properties of virus-like particles have been used in vaccine development. Vaccination has saved many lives and vitally improved global health and life conditions. Nanobiotechnology could increase vaccine development. Nanoparticles, including virus-like particles, have extensive potential as vaccine vehicles, epitope carriers, adjuvants, and other nanobiomedical tools. This Issue will be focused on nanobiotechnology applied in construction or modification of virus-like particles and vaccine development. Therefore, we welcome research articles, short communications, as well as review articles, of a high scientific level on the nanotechnological aspects of molecular virology, vaccinology, and immunology.

Guest Editors

Prof. Dr. Kamil Kuca

Prof. Dr. Jakub D. Rybka

Prof. Dr. Tomasz Pniewski

Deadline for manuscript submissions

closed (28 February 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/63544

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).